Biotech plunges 17% as cancer drug fails

BRITISH BIOTECH yesterday added another chapter to its disastrous history when it revealed that its star anti-cancer drug had failed a key clinical trial.

Shares in the beleaguered drug company plunged over 17 per cent to an all-time low of 21.5p after it admitted that Marimastat, one of its most advanced compounds, did not work in the treatment of pancreatic tumours.

Industry experts said the result cast doubts over Marismatat's efficacy and could jeopardise a major part of British Biotech's clinical programme.

The failure of the 400-patient test is a huge blow for the company as it had been predicted over 15 months ago by Andrew Millar, the group's former head of clinical trials.

Mr Millar was sacked in April for looking at confidential data in the trial - a procedure known as "unblinding" - and for expressing concerns to shareholders over the efficacy of marimastat and the anti-pancreatitis compound Zacutex.

The affair sparked a bitter row between Mr Millar and the board, which caused a collapse in the share price from its peak of over pounds 3 and led to the departure of the chief executive, Keith McCullagh.

Mr Millar yesterday said: "We knew this in December 1997. I feel terribly sorry that the right management of a potential new drug was not undertaken."

The new chief executive, Elliot Goldstein, yesterday said that the study's negative results did not spell the end of Marimastat.

He said the test showed that the drug had failed its target of a 16 per cent reduction in death rates compared with an existing drug. However, he said pancreatic cancer was one of the most difficult cancers to treat and that further studies were needed to assess Marimastat's efficacy.

British Biotech was spending around half of its pounds 24m development budget to trial the drug on different forms of cancer in nine other studies and results were expected over the next 12 month. "We are not deciding to quit. The plan is to bring the nine studies to their end," Dr Goldstein said.

Peder Jensen, the development director, denied that the failure of the trials vindicated Dr Millar's actions. He said that when Dr Millar unblinded the study, he could not have predicted the outcome because the data was too scant. "He just happened to be right," Mr Jensen said.

Mr Millar, who is embroiled in a legal case with the company set to be heard in the High Court later this year, rejected the suggestion. "It is a virtual mathematical certainty that this was to happen".

He predicted that the other study he unblinded, a key trial for Zacutex, was also set to fail. The company said it would report on the trial before the end of next month.

City analysts said the result of the trial would prompt investors to reduce their estimates of Marimastat's future earnings. The drug was once hailed as a potential blockbuster with estimated sales of over $1bn a year.

However, a series of setbacks has prompted experts to revise sales predictions to $200m.

Start your day with The Independent, sign up for daily news emails
Life and Style
Steve Shaw shows Kate how to get wet behind the ears and how to align her neck
healthSteven Shaw - the 'Buddha of Breaststroke' - applies Alexander Technique to the watery sport
Arts and Entertainment
The sight of a bucking bronco in the shape of a pink penis was too much for Hollywood actor and gay rights supporter Martin Sheen, prompting him to boycott a scene in the TV series Grace and Frankie
Arts and Entertainment
Lena Headey as Cersei Lannister
TVSPOILER ALERT: It's all coming together as series returns to form
footballShirt then goes on sale on Gumtree
Terry Sue-Patt as Benny in the BBC children’s soap ‘Grange Hill’
voicesGrace Dent on Grange Hill and Terry Sue-Patt
Arts and Entertainment
Performers drink tea at the Glastonbury festival in 2010
Arts and Entertainment
Twin Peaks stars Joan Chen, Michael Ontkean, Kyle Maclachlan and Piper Laurie
tvName confirmed for third series
Cameron Jerome
footballCanaries beat Boro to gain promotion to the Premier League
Arts and Entertainment
ebookA unique anthology of reporting and analysis of a crucial period of history
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Guru Careers: Software Developer / C# Developer

£40-50K: Guru Careers: We are seeking an experienced Software / C# Developer w...

Neil Pavier: Management Accountant

£45,000 - £55,000: Neil Pavier: Are you looking for your next opportunity for ...

Sheridan Maine: Commercial Accountant

£45,000 - £55,000: Sheridan Maine: Are you a newly qualified ACA/ACCA/ACMA qua...

Laura Norton: Project Accountant

£50,000 - £60,000: Laura Norton: Are you looking for an opportunity within a w...

Day In a Page

Abuse - and the hell that came afterwards

Abuse - and the hell that follows

James Rhodes on the extraordinary legal battle to publish his memoir
Why we need a 'tranquility map' of England, according to campaigners

It's oh so quiet!

The case for a 'tranquility map' of England
'Timeless fashion': It may be a paradox, but the industry loves it

'Timeless fashion'

It may be a paradox, but the industry loves it
If the West needs a bridge to the 'moderates' inside Isis, maybe we could have done with Osama bin Laden staying alive after all

Could have done with Osama bin Laden staying alive?

Robert Fisk on the Fountainheads of World Evil in 2011 - and 2015
New exhibition celebrates the evolution of swimwear

Evolution of swimwear

From bathing dresses in the twenties to modern bikinis
Sun, sex and an anthropological study: One British academic's summer of hell in Magaluf

Sun, sex and an anthropological study

One academic’s summer of hell in Magaluf
From Shakespeare to Rising Damp... to Vicious

Frances de la Tour's 50-year triumph

'Rising Damp' brought De la Tour such recognition that she could be forgiven if she'd never been able to move on. But at 70, she continues to flourish - and to beguile
'That Whitsun, I was late getting away...'

Ian McMillan on the Whitsun Weddings

This weekend is Whitsun, and while the festival may no longer resonate, Larkin's best-loved poem, lives on - along with the train journey at the heart of it
Kathryn Williams explores the works and influences of Sylvia Plath in a new light

Songs from the bell jar

Kathryn Williams explores the works and influences of Sylvia Plath
How one man's day in high heels showed him that Cannes must change its 'no flats' policy

One man's day in high heels

...showed him that Cannes must change its 'flats' policy
Is a quiet crusade to reform executive pay bearing fruit?

Is a quiet crusade to reform executive pay bearing fruit?

Dominic Rossi of Fidelity says his pressure on business to control rewards is working. But why aren’t other fund managers helping?
The King David Hotel gives precious work to Palestinians - unless peace talks are on

King David Hotel: Palestinians not included

The King David is special to Jerusalem. Nick Kochan checked in and discovered it has some special arrangements, too
More people moving from Australia to New Zealand than in the other direction for first time in 24 years

End of the Aussie brain drain

More people moving from Australia to New Zealand than in the other direction for first time in 24 years
Meditation is touted as a cure for mental instability but can it actually be bad for you?

Can meditation be bad for you?

Researching a mass murder, Dr Miguel Farias discovered that, far from bringing inner peace, meditation can leave devotees in pieces
Eurovision 2015: Australians will be cheering on their first-ever entrant this Saturday

Australia's first-ever Eurovision entrant

Australia, a nation of kitsch-worshippers, has always loved the Eurovision Song Contest. Maggie Alderson says it'll fit in fine